SynthesisIntensive care medicine2011
Influence of hydroxyethyl starch (HES) 130/0.4 on hemostasis as measured by viscoelastic device analysis: a systematic review.
Synthesis in Intensive care medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01849757 (Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery: HES 130/0.4 or Albumin 5%
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Fluid replacement with hydroxyethyl starch in critical care--a reassessment.Deutsches Arzteblatt international · 2013Pooled it
- Trial
- Effect of synthetic colloid administration on coagulation in healthy dogs and dogs with systemic inflammation.Journal of veterinary internal medicine · 2015Trial
- Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate.Intensive care medicine · 2014Trial
- Stroke volume-directed administration of hydroxyethyl starch (HES 130/0.4) and Ringer’s acetate in prone position during neurosurgery: a randomized controlled trial.Journal of anesthesia · 2014Trial
- Bleeding and risk of death with hydroxyethyl starch in severe sepsis: post hoc analyses of a randomized clinical trial.Intensive care medicine · 2013Trial
- The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro.Blood transfusion = Trasfusione del sangue · 2013Trial
- Institutional modified post esophagectomy care protocol offers improved perioperative outcomes - a single-center propensity score matched analysis.World journal of surgical oncology · 2026Article
- Gelatin 4% and hydroxyethyl starch (130/0.42) impair clot formation in a human ex vivo whole-blood resuscitation model.Scandinavian journal of trauma, resuscitation and emergency medicine · 2026Article
- Perioperative micro-arterial function and extravasation in cytoreductive ovarian cancer surgery: an observational study.Intensive care medicine experimental · 2026Article
- Goal-directed fluid therapy using uncalibrated pulse contour analysis and balanced crystalloid solutions during hip revision arthroplasty: a quality implementation project.Journal of orthopaedic surgery and research · 2023Observational
- The effects of hydroxyethyl starch and gelatine on lung tissue and coagulation during the resuscitation of rats with traumatic haemorrhagic shock.Anaesthesiology intensive therapy · 2022Article
- Validation of the relationship between coagulopathy and localization of hydroxyethyl starch on the vascular endothelium in a rat hemodilution model.Scientific reports · 2021Article
- Effect of Goal-Directed Crystalloid versus Colloid Administration on Perioperative Hemostasis in Partial Hepatectomy: A Randomized, Controlled Trial.Journal of clinical medicine · 2021Article
- Colloids Yes or No? - a "Gretchen Question" Answered.Frontiers in veterinary science · 2021Review
- Inflammation and coagulation following minimally invasive extracorporeal circulation technologies.Journal of thoracic disease · 2019Review
- Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution.PloS one · 2019Article
- Synthetic colloid resuscitation in severely injured patients: analysis of a nationwide trauma registry (TraumaRegister DGU).Scientific reports · 2018Article
- Is the literature inconclusive about the harm from HES? No.Intensive care medicine · 2017Article
- Effect of Hemodilution In Vitro with Hydroxyethyl Starch on Hemostasis.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHydroxyethyl starch solutions (HES) are plasma volume expanders which affect hemostasis. Newer HES 130/0.4 is said to be safer. Reevaluation of published evidence is necessary after the recent retraction of studies.
methodsSystematic review of studies assessing HES 130/0.4 effects on hemostasis by thrombelastography (TEG, ROTEM) or Sonoclot (SCR) in comparison with crystalloid or albumin control fluids was performed. Only studies which provided statistical comparisons between study fluids were analyzed. Studies were divided into in vitro or in vivo hemodilution studies. We assessed study quality, HES effects which differed significantly from controls, values outside normal range, degree of hemodilution, and cumulative HES dose.
resultsSeventeen in vitro and seven in vivo hemodilution studies were analyzed. Four studies reported quality control measures. Nineteen studies (all 15 ROTEM studies, 3 of 5 in vitro TEG, and 1 of 2 SCR studies) showed a significant hypocoagulatory effect of HES 130/0.4 on clot formation, while clotting time was not uniformly affected. Three in vivo TEG studies with low HES doses or cancer patients found mixed or nonsignificant results. In studies which provided normal ranges (n = 9), more values were outside normal ranges in the HES than in the control groups (87/122 vs. 58/122, p < 0.001). Dose effects were apparent in the in vitro studies, which investigated higher dilutions up to 80%. In vivo studies were fewer and did not investigate doses >40 ml/kg.
conclusionsHES 130/0.4 administration results in a weaker and smaller clot. Until results from well-designed clinical trials are available, safer fluids should be chosen for patients with impaired coagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.